Avadel Pharmaceuticals

NASDAQ: AVDL · Real-Time Price · USD
13.69
0.19 (1.41%)
At close: Aug 15, 2025, 3:59 PM
13.69
0.04%
After-hours: Aug 15, 2025, 04:10 PM EDT

Avadel Pharmaceuticals Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
169.12M 27.96M n/a n/a
Cost of Revenue
15.28M 846K 1.49M 815K
Gross Profit
153.84M 27.12M -1.49M -815K
Operating Income
-42.4M -137.85M -98.56M -85.55M
Interest Income
n/a n/a 11.12M 2.13M
Pretax Income
-49.08M -160.78M -111.44M -93.14M
Net Income
-48.83M -160.28M -137.46M -77.33M
Selling & General & Admin
181.04M 151.71M 74.52M 68.5M
Research & Development
15.2M 13.26M 20.7M 17.1M
Other Expenses
n/a n/a 3.35M 217K
Operating Expenses
196.24M 164.97M 95.22M 85.6M
Interest Expense
10.83M 9.89M 12.34M 9.94M
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
211.52M 165.81M 95.22M 85.6M
Income Tax Expense
-247K -501K 26.02M -15.82M
Shares Outstanding (Basic)
95.14M 80.17M 60.09M 58.53M
Shares Outstanding (Diluted)
95.14M 80.17M 60.09M 58.53M
EPS (Basic)
-0.51 -2 -2.29 -1.32
EPS (Diluted)
-0.51 -2 -2.29 -1.32
EBITDA
-35.57M -149.13M -97.6M -84.78M
EBIT
-38.25M -150.89M -99.1M -83.2M
Depreciation & Amortization
2.68M 1.77M 1.49M 815K